Identification of anoikis-related molecular patterns to define tumor microenvironment and predict immunotherapy response and prognosis in soft-tissue sarcoma

Background: Soft-tissue sarcoma (STS) is a massive threat to human health due to its high morbidity and malignancy. STS also represents more than 100 histologic and molecular subtypes, with different prognosis. There is growing evidence that anoikis play a key role in the proliferation and invasion of tumors. However, the effects of anoikis in the immune landscape and the prognosis of STS remain unclear. Methods: We analyzed the genomic and transcriptomic profiling of 34 anoikis-related genes (ARGs) in patient cohort of pan-cancer and STS from The Cancer Genome Atlas (TCGA) database. Single-cell transcriptome was used to disclose the expression patterns of ARGs in specific cell types. Gene expression was further validated by real-time PCR and our own sequencing data. We established the Anoikis cluster and Anoikis subtypes by using unsupervised consensus clustering analysis. An anoikis scoring system was further built based on the differentially expressed genes (DEGs) between Anoikis clusters. The clinical and biological characteristics of different groups were evaluated. Results: The expressions of most ARGs were significantly different between STS and normal tissues. We found some common ARGs profiles across the pan-cancers. Network of 34 ARGs demonstrated the regulatory pattern and the association with immune cell infiltration. Patients from different Anoikis clusters or Anoikis subtypes displayed distinct clinical and biological characteristics. The scoring system was efficient in prediction of prognosis and immune cell infiltration. In addition, the scoring system could be used to predict immunotherapy response. Conclusion: Overall, our study thoroughly depicted the anoikis-related molecular and biological profiling and interactions of ARGs in STS. The Anoikis score model could guide the individualized management.

[1]  Huiren Tao,et al.  Anoikis patterns exhibit distinct prognostic and immune landscapes in Osteosarcoma. , 2023, International immunopharmacology.

[2]  Zhu Weiwei,et al.  An anoikis-based signature for predicting prognosis in hepatocellular carcinoma with machine learning , 2023, Frontiers in Pharmacology.

[3]  Haowen Chen,et al.  TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR , 2022, International journal of biological sciences.

[4]  A. Alimonti,et al.  Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer , 2022, Nature Communications.

[5]  M. Benelli,et al.  PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer , 2022, NPJ breast cancer.

[6]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[7]  Robert F. Gruener,et al.  oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data , 2021, Briefings Bioinform..

[8]  Q. Zou,et al.  Correction: IQGAP1 promotes anoikis resistance and metastasis through Rac1-dependent ROS accumulation and activation of Src/FAK signalling in hepatocellular carcinoma , 2021, British Journal of Cancer.

[9]  Christopher S. Hughes,et al.  Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing Sarcoma , 2021, Cancer discovery.

[10]  D. Nitti,et al.  E2F1 copy number variations in germline and breast cancer: a retrospective study of 222 Italian women , 2021, Molecular medicine.

[11]  Hannah R. Weisman,et al.  Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma , 2021, Nature Medicine.

[12]  M. Delorenzi,et al.  Tailoring the resolution of single-cell RNA sequencing for primary cytotoxic T cells , 2021, Nature Communications.

[13]  X. Zu,et al.  Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer , 2021, Theranostics.

[14]  V. Seshan,et al.  The association between tumor mutational burden and prognosis is dependent on treatment context , 2020, Nature genetics.

[15]  Wei-Chun Chang,et al.  Genomic Biomarkers of Survival in Patients with Adenocarcinoma of the Uterine Cervix Receiving Chemoradiotherapy , 2020, International journal of molecular sciences.

[16]  A. Gronchi,et al.  Soft‐tissue sarcoma in adults: An update on the current state of histiotype‐specific management in an era of personalized medicine , 2020, CA: a cancer journal for clinicians.

[17]  F. Bertucci,et al.  Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Matthew D. Smith,et al.  Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy. , 2019, The Journal of clinical investigation.

[19]  D. Jackson,et al.  Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. , 2019, Cancer cell.

[20]  S. Mocellin,et al.  E2F1 germline copy number variations and melanoma susceptibility , 2019, Journal of translational medicine.

[21]  U. Röhrig,et al.  Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond , 2019, Nature Reviews Drug Discovery.

[22]  J. Madore,et al.  Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. , 2019, Cancer cell.

[23]  C. Frezza Histidine metabolism boosts cancer therapy , 2018, Nature.

[24]  R. Bourgon,et al.  TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.

[25]  Christian M. Metallo,et al.  The PLAG1-GDH1 Axis Promotes Anoikis Resistance and Tumor Metastasis through CamKK2-AMPK Signaling in LKB1-Deficient Lung Cancer. , 2018, Molecular cell.

[26]  Steven J. M. Jones,et al.  Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas , 2017, Cell.

[27]  Giuseppe Opocher,et al.  Copy number variations of E2F1: a new genetic risk factor for testicular cancer. , 2017, Endocrine-related cancer.

[28]  Emanuel J. V. Gonçalves,et al.  A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.

[29]  S. Ogino,et al.  Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  S. Nie,et al.  Copy‐number variation of MCL1 predicts overall survival of non‐small‐cell lung cancer in a Southern Chinese population , 2016, Cancer medicine.

[31]  I. Peták,et al.  Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma , 2016, Virchows Archiv.

[32]  Yan Xu,et al.  Anoikis resistance is a critical feature of highly aggressive ovarian cancer cells , 2014, Oncogene.

[33]  Khin Thway,et al.  Systemic treatment of soft-tissue sarcoma—gold standard and novel therapies , 2014, Nature Reviews Clinical Oncology.

[34]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[35]  Chris Sander,et al.  Emerging landscape of oncogenic signatures across human cancers , 2013, Nature Genetics.

[36]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[37]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..

[38]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[39]  E. Giannoni,et al.  Anoikis: an emerging hallmark in health and diseases , 2012, The Journal of pathology.

[40]  Matthew D. Wilkerson,et al.  ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking , 2010, Bioinform..

[41]  N. Kyprianou,et al.  Targeting anoikis resistance in prostate cancer metastasis. , 2010, Molecular aspects of medicine.

[42]  W. Lam,et al.  PIK3CA mutations and copy number gains in human lung cancers. , 2008, Cancer research.

[43]  P. Sorensen,et al.  E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. , 2007, Cancer research.

[44]  O. Myklebost,et al.  Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential , 2007, BMC Genomics.

[45]  J. Averill,et al.  Increased gene copy number of The transcription factor E2F1 In malignant melanoma , 2006, Cancer biology & therapy.

[46]  D. Rose,et al.  Obesity, adipocytokines, and insulin resistance in breast cancer , 2004, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[47]  David Botstein,et al.  Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans. , 2003, The American journal of pathology.

[48]  D. Botstein,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[49]  T. Eckes,et al.  A Graph Theoretic Criterion for Determining the Number of Clusters in a Data Set. , 1992, Multivariate behavioral research.